For research use only. Not for therapeutic Use.
SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1[1].
Catalog Number | I040937 |
CAS Number | 2882823-03-0 |
Synonyms | 5-chloro-4-fluoro-2-hydroxy-N-[4-(trifluoromethoxy)phenyl]benzamide |
Molecular Formula | C14H8ClF4NO3 |
Purity | ≥95% |
InChI | InChI=1S/C14H8ClF4NO3/c15-10-5-9(12(21)6-11(10)16)13(22)20-7-1-3-8(4-2-7)23-14(17,18)19/h1-6,21H,(H,20,22) |
InChIKey | AGOOHZQXJABZCD-UHFFFAOYSA-N |
SMILES | C1=CC(=CC=C1NC(=O)C2=CC(=C(C=C2O)F)Cl)OC(F)(F)F |
Reference | [1]. Rui Li, et al. Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2. Eur J Med Chem. 2023 May 5;253:115320. |